Isoniazid + rifampicin

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.5. Antituberculosis medicines

EMLc ATC codes: J04AM02

Indication	Tuberculosis ICD11 code: 1B1Z
INN	Isoniazid + rifampicin
Medicine type	Chemical agent
List type	Core
Additional notes	WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.
Formulations	**Oral > Solid > dispersible tablet:** 50 mg + 75 mg (EMLc) **Oral > Solid > tablet:** 75 mg + 150 mg (EML) ; 150 mg + 300 mg (EML)
EML status history	First added in 1989 (TRS 796) Changed in 1995 (TRS 867) Changed in 1997 (TRS 882) Changed in 1999 (TRS 895) Changed in 2007 (TRS 950) Changed in 2009 (TRS 958) Changed in 2017 (TRS 1006) Changed in 2019 (TRS 1021)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Isoniazid + rifampicin
DrugBank	Isoniazid, Rifampicin

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the deletion of the 60 mg + 60 mg and 150 mg + 150 mg formulations of isoniazid + rifampicin for intermittent use three times weekly from the core list of the EML, noting the advice of the WHO Global TB Programme that their use is no longer recommended in current WHO guidelines based on evidence that patients who received three times weekly dosing had a higher risk of treatment failure, disease relapse and acquired drug resistance compared with patients who received daily dosing (1). References: 1. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017.